ArticleWorld journal of microbiology & biotechnology2018
Antifungal activity of magnoflorine against Candida strains.
Article in World journal of microbiology & biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 67 citations in OpenAlex.
- Exploration of the therapeutic potential of magnoflorine against osteoarthritis progression using network pharmacology and in vitro validation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Magnoflorine alleviates colitis-induced anxiety-like behaviors by regulating gut microbiota and microglia-mediated neuroinflammation.Microbiome · 2025Article
- Exploring the Arsenal of Novel Antifungal Drug Targets for Combating Fungal Infections.Current pharmaceutical biotechnology · 2025Review
- Mitigating candidiasis with acarbose by targeting Candida albicans α-glucosidase: in-silico, in-vitro and transcriptomic approaches.Scientific reports · 2024Article
- Inhibition ofAntibiotics (Basel, Switzerland) · 2024Article
- A Comprehensive Review on Potential In Silico Screened Herbal Bioactive Compounds and Host Targets in the Cardiovascular Disease Therapy.BioMed research international · 2024Review
- A Combination of Magnoflorine and Spinosin Improves the Antidepressant effects on CUMS Mouse Model.Current drug metabolism · 2024Article
- The potential role of plant secondary metabolites on antifungal and immunomodulatory effect.Applied microbiology and biotechnology · 2023Review
- Phytochemicals as Invaluable Sources of Potent Antimicrobial Agents to Combat Antibiotic Resistance.Life (Basel, Switzerland) · 2023Review
- Anti-Journal of fungi (Basel, Switzerland) · 2023Article
- Molecular association ofFrontiers in cellular and infection microbiology · 2023Review
- The Cytotoxic and Inhibitory Effects of Plant Derivatives onMolecules (Basel, Switzerland) · 2022Article
- Antibiofilm Effect of Cinnamaldehyde-Chitosan Nanoparticles against the Biofilm ofAntibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial activities and mechanisms of extract and components of herbs in East Asia.RSC advances · 2022Review
- Targeting Virulence Factors ofFoods (Basel, Switzerland) · 2022Review
- Antibacterial and Antifungal Alkaloids from Asian Angiosperms: Distribution, Mechanisms of Action, Structure-Activity, and Clinical Potentials.Antibiotics (Basel, Switzerland) · 2022Review
- Pectolinarin Inhibits the Bacterial Biofilm Formation and Thereby Reduces Bacterial Pathogenicity.Antibiotics (Basel, Switzerland) · 2022Article
- Emerging Antifungal Targets and Strategies.International journal of molecular sciences · 2022Review
- Natural Products-Based Metallic Nanoparticles as Antimicrobial Agents.Frontiers in pharmacology · 2022Review
- Natural products from traditional medicine as promising agents targeting at different stages of oral biofilm development.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans is a major invasive pathogen, and the development of strains resistant to conventional antifungal agents has been reported in recent years. We evaluated the antifungal activity of 44 compounds against Candida strains. Magnoflorine showed the highest growth inhibitory activity of the tested Candida strains, with a minimum inhibitory concentration (MIC) of 50 μg/mL based on microdilution antifungal susceptibility testing. Disk diffusion assay confirmed the antifungal activity of magnoflorine and revealed that this activity was stable over 3 days compared to those of berberine and cinnamaldehyde. Cytotoxicity testing showed that magnoflorine could potentially be used in a clinical setting because it didn't have any toxicity to HaCaT cells even in 200 μg/mL of treatment. Magnoflorine at 50 μg/mL inhibited 55.91 ± 7.17% of alpha-glucosidase activity which is required for normal cell wall composition and virulence of Candida albicans. Magnoflorine also reduced the formation of C. albicans' biofilm. Combined treatment with magnoflorine and miconazole decreased the amount of miconazole required to kill various Candida albicans. Therefore, magnoflorine is a good candidate lead compound for novel antifungal agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.